Hospital
Summersville Regional Medical Center
Summersville Regional Medical Center was paid $3.37M by Medicaid between Jan 2018 and Jun 2019, across 167 billing codes. Its largest line is 99284, emergency room visit (serious) — 7.8% of everything it billed.
33Billing provider infoSUMMERSVILLE REGIONAL MEDICAL CENTER
SUMMERSVILLE, WV 26651
SUMMERSVILLE, WV 26651
33aNPI1104813740assigned 09/29/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$3.37M
24GClaims100,135
24DCodes billed167
24AFirst – last monthJan 2018 – Jun 2019
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in West Virginia
Rank by total paid#4 of 5
Median peer was paid$6.61M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,103 | $2.38M | |
| 2019 | 22,032 | $990K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 3,626 | 3,107 | $263K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 3,434 | 3,044 | $194K |
| 36415 | Collection of venous blood by venipuncture | 5.3% | 8,656 | 6,107 | $178K |
| 80053 | Comprehensive metabolic panel | 5.3% | 5,722 | 4,491 | $178K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.3% | 5,930 | 4,789 | $144K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 743 | 677 | $138K |
| 81001 | 2.6% | 3,340 | 2,907 | $87K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 2,041 | 1,773 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 1,862 | 1,504 | $64K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 1,881 | 1,549 | $64K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.9% | 1,549 | 1,004 | $63K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 2,471 | 1,938 | $63K |
155 more codes
| J2704 | Injection, propofol, 10 mg | 1.7% | 1,267 | $57K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.7% | 1,461 | $56K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 897 | $54K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.6% | 2,008 | $53K |
| 85027 | 1.6% | 2,034 | $53K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 531 | $52K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1.5% | 1,434 | $51K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 420 | $49K |
| 84703 | 1.4% | 1,111 | $49K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 714 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 873 | $46K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 910 | $46K |
| 84484 | 1.3% | 2,220 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 1,497 | $44K |
| 83690 | 1.2% | 1,582 | $41K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 576 | $39K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 1,638 | $39K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1.1% | 988 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 2,113 | $35K |
| 96376 | 1.0% | 788 | $34K | |
| 82150 | <1% | 1,181 | $33K | |
| 87040 | <1% | 1,012 | $32K | |
| 82553 | <1% | 1,309 | $29K | |
| 83605 | <1% | 942 | $28K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 255 | $27K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,035 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 711 | $26K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 562 | $25K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 340 | $25K |
| 82550 | <1% | 1,387 | $24K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 657 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,370 | $22K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 512 | $20K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 434 | $20K |
| 85610 | <1% | 1,222 | $18K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 937 | $17K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 726 | $17K |
| 85730 | <1% | 905 | $17K | |
| 86140 | <1% | 553 | $16K | |
| 85378 | <1% | 469 | $16K | |
| J3490 | Unclassified drugs | <1% | 465 | $15K |
| 80061 | Lipid panel | <1% | 787 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 749 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 191 | $14K |
| 73562 | <1% | 432 | $14K | |
| 85007 | <1% | 808 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 212 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 551 | $13K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 547 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 176 | $12K |
| 76770 | <1% | 216 | $12K | |
| 83735 | <1% | 535 | $12K | |
| 93017 | <1% | 79 | $12K | |
| 72110 | <1% | 274 | $11K | |
| 84439 | <1% | 448 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 271 | $9K |
| 93971 | <1% | 176 | $9K | |
| 83880 | <1% | 364 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 352 | $9K |
| 73610 | <1% | 252 | $8K | |
| 73130 | <1% | 223 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 481 | $8K |
| 87186 | <1% | 495 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 311 | $7K |
| 76830 | Ultrasound, transvaginal | <1% | 133 | $7K |
| 73030 | <1% | 247 | $7K | |
| 88342 | <1% | 88 | $6K | |
| 87081 | <1% | 292 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 257 | $6K |
| J1815 | Injection, insulin, per 5 units | <1% | 369 | $6K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 194 | $5K |
| 76536 | <1% | 93 | $5K | |
| 73630 | <1% | 239 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 109 | $5K |
| 73110 | <1% | 89 | $5K | |
| 72050 | <1% | 115 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $5K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 38 | $5K |
| 74019 | <1% | 170 | $4K | |
| 90715 | <1% | 90 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 73 | $4K |
| 76642 | <1% | 82 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 292 | $4K |
| 74018 | <1% | 230 | $4K | |
| 78227 | <1% | 14 | $4K | |
| 82607 | <1% | 147 | $4K | |
| 71250 | <1% | 57 | $4K | |
| 85651 | <1% | 261 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 150 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $4K |
| 93880 | <1% | 16 | $4K | |
| 72100 | <1% | 135 | $3K | |
| 73502 | <1% | 126 | $3K | |
| 86901 | <1% | 98 | $3K | |
| 86900 | <1% | 98 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 86 | $3K |
| 83540 | <1% | 172 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 110 | $3K |
| 82570 | <1% | 191 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 108 | $3K |
| 72072 | <1% | 76 | $3K | |
| 86850 | <1% | 93 | $3K | |
| 82728 | <1% | 117 | $3K | |
| 94761 | <1% | 190 | $2K | |
| 80074 | <1% | 78 | $2K | |
| 72131 | <1% | 33 | $2K | |
| 86756 | <1% | 88 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 79 | $2K |
| 74022 | <1% | 67 | $2K | |
| 87070 | <1% | 116 | $2K | |
| 82043 | <1% | 90 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 56 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 40 | $2K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 66 | $1K |
| 88304 | <1% | 40 | $1K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 67 | $1K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 15 | $1K |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 75 | $1K |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 32 | $1K |
| 73090 | <1% | 18 | $1K | |
| 51702 | <1% | 106 | $1K | |
| 84436 | <1% | 62 | $1K | |
| 84479 | <1% | 46 | $927.53 | |
| 84702 | <1% | 38 | $848.77 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $824.96 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 79 | $735.08 |
| 93225 | <1% | 32 | $664.73 | |
| 80076 | <1% | 16 | $624.09 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 50 | $606.84 |
| 82784 | <1% | 35 | $595.41 | |
| 97035 | <1% | 28 | $461.48 | |
| 86592 | <1% | 28 | $392.30 | |
| 83516 | <1% | 17 | $391.81 | |
| 97014 | <1% | 43 | $391.64 | |
| 73590 | <1% | 12 | $385.36 | |
| 82140 | <1% | 12 | $368.62 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 16 | $292.45 |
| 73080 | <1% | 16 | $171.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 44 | $148.67 |
| 87210 | <1% | 17 | $141.14 | |
| 87220 | <1% | 17 | $139.46 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 17 | $135.68 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 19 | $100.17 |
| G0378 | Hospital observation service, per hour | <1% | 13 | $95.12 |
| 51701 | <1% | 13 | $90.93 | |
| 86255 | <1% | 16 | $64.11 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 16 | $20.90 |
| 94664 | <1% | 12 | $14.80 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 127 | $0.00 |
| 1036F | 0% | 128 | $0.00 | |
| 1123F | 0% | 13 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 28 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 184 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 106 | $0.00 |
| 4004F | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKINCELL, DEBORAH (REVENUE CYCLE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Summersville Regional Medical Center | Summersville, WV | $231K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.